Compass Therapeutics (CMPX) Total Current Liabilities (2023 - 2025)
Historic Total Current Liabilities for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $12.4 million.
- Compass Therapeutics' Total Current Liabilities rose 17999.1% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 17999.1%. This contributed to the annual value of $8.9 million for FY2024, which is 1375.46% up from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Total Current Liabilities is $12.4 million, which was up 17999.1% from $13.9 million recorded in Q2 2025.
- Compass Therapeutics' Total Current Liabilities' 5-year high stood at $14.9 million during Q1 2025, with a 5-year trough of $3.9 million in Q1 2024.
- In the last 3 years, Compass Therapeutics' Total Current Liabilities had a median value of $9.5 million in 2024 and averaged $9.6 million.
- Its Total Current Liabilities has fluctuated over the past 5 years, first tumbled by 6521.0% in 2024, then skyrocketed by 28273.82% in 2025.
- Over the past 3 years, Compass Therapeutics' Total Current Liabilities (Quarter) stood at $7.8 million in 2023, then grew by 13.75% to $8.9 million in 2024, then skyrocketed by 39.87% to $12.4 million in 2025.
- Its Total Current Liabilities stands at $12.4 million for Q3 2025, versus $13.9 million for Q2 2025 and $14.9 million for Q1 2025.